DK1684719T3 - Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger - Google Patents

Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger

Info

Publication number: DK1684719T3
Authority: DK; Denmark
Prior art keywords: compositions; alpha; antitrypsin; treatment methods; aat
Prior art date: 2003-11-14

Application number

DK04811377.3T

Other languages

English (en)

Inventor

Harish Kumar

Timothy Kreiger

Ken Kabingue

Virginia Mosher

Philip J Barr

Ian C Bathurst

Manzer J Durrani

Original Assignee

Baxter Int

Baxter Healthcare Sa

Arriva Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-14

Filing date

2004-11-11

Publication date

2012-01-30

2004-11-11 Application filed by Baxter Int, Baxter Healthcare Sa, Arriva Pharmaceuticals Inc filed Critical Baxter Int

2012-01-30 Application granted granted Critical

2012-01-30 Publication of DK1684719T3 publication Critical patent/DK1684719T3/da

Links

239000000203 mixture Substances 0.000 title abstract 7
102000015395 alpha 1-Antitrypsin Human genes 0.000 title abstract 2
108010050122 alpha 1-Antitrypsin Proteins 0.000 title abstract 2
229940024142 alpha 1-antitrypsin Drugs 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
238000009472 formulation Methods 0.000 abstract 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
208000019693 Lung disease Diseases 0.000 abstract 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
239000000443 aerosol Substances 0.000 abstract 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
239000003963 antioxidant agent Substances 0.000 abstract 1
230000003078 antioxidant effect Effects 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000012669 liquid formulation Substances 0.000 abstract 1
238000002663 nebulization Methods 0.000 abstract 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
229920000053 polysorbate 80 Polymers 0.000 abstract 1
229940068968 polysorbate 80 Drugs 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
-1 trehalose Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
Dispersion Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

DK04811377.3T 2003-11-14 2004-11-11 Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger DK1684719T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US52054903P	2003-11-14	2003-11-14
PCT/US2004/038650 WO2005048985A2 (en)	2003-11-14	2004-11-11	Alpha 1-antitrypsin compositions and treatment methods using such compositions

Publications (1)

Publication Number	Publication Date
DK1684719T3 true DK1684719T3 (da)	2012-01-30

Family

ID=34619481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04811377.3T DK1684719T3 (da)	2003-11-14	2004-11-11	Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger

Country Status (12)

Country	Link
US (2)	US20080312136A1 (da)
EP (1)	EP1684719B1 (da)
JP (1)	JP2007511539A (da)
AT (1)	ATE530165T1 (da)
AU (1)	AU2004290587B2 (da)
CA (1)	CA2545855A1 (da)
DK (1)	DK1684719T3 (da)
ES (1)	ES2375706T3 (da)
PL (1)	PL1684719T3 (da)
PT (1)	PT1684719E (da)
SI (1)	SI1684719T1 (da)
WO (1)	WO2005048985A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2559062A1 (en) *	2004-03-09	2005-09-22	Arriva Pharmaceuticals, Inc.	Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
PL1981572T3 (pl)	2006-02-09	2013-05-31	Kamada Ltd	Dostarczanie inhibitora alfa-1 proteinazy do płuc
TW200938222A (en) *	2007-12-13	2009-09-16	Glaxo Group Ltd	Compositions for pulmonary delivery
CA2779369C (en)	2009-11-03	2018-06-19	Grifols Therapeutics Inc.	Composition, method, and kit for alpha-1 proteinase inhibitor
JP5810091B2 (ja)	2009-11-24	2015-11-11	グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	凍結乾燥方法、組成物、及びキット
NZ629256A (en) *	2009-12-22	2016-02-26	Celldex Therapeutics Inc	Vaccine compositions
EP2758065B1 (en) *	2011-12-30	2021-06-23	Grifols, S.A.	Alpha1-proteinase inhibitor for use in delaying the onset or progression of pulmonary exacerbations
EP3708182A1 (en) *	2013-03-29	2020-09-16	The Regents Of The University Of Colorado	Compositions and methods for preparing a subject for organ or non-organ implantation
EP3155117A4 (en) *	2014-06-11	2017-11-22	Beth Israel Deaconess Medical Center, Inc.	Alpha1-antitrypsin compositions and methods of treating autoimmune diseases
WO2018116300A1 (en) *	2016-12-22	2018-06-28	Kamada Ltd.	Dry powder formulations of alpha-1 antitrypsin
EP3585423A4 (en) *	2017-02-21	2020-12-23	Kamada Ltd.	METHODS AND USES OF ALPHA-1-ANTITRYPSINE FOR EARLY INTERVENTION IN LUNG DISEASES
US12031144B2 (en)	2017-03-29	2024-07-09	Cornell University	Oxidation-resistant AAT gene therapy
EP3703733A4 (en) *	2017-10-31	2021-08-04	Kamada Ltd	METHODS AND COMPOSITIONS FOR REDUCING LUNG DAMAGE ASSOCIATED WITH PULMONARY TRANSPLANTATION
IL267923B2 (en) *	2018-08-02	2023-06-01	Grifols Worldwide Operations Ltd	The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
JP2023507989A (ja) *	2019-12-20	2023-02-28	クリスタルバイオテックインコーポレイテッド	気道及び／または肺への遺伝子送達のための組成物及び方法
GB202102258D0 (en) *	2021-02-17	2021-03-31	Arecor Ltd	Novel composition

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4150071A (en) *	1977-08-26	1979-04-17	Respiratory Care, Inc.	Nebulizer
IT1105653B (it) *	1978-06-20	1985-11-04	Craighero Margherita	Apparecchio aerosolizzatore
US4253468A (en) *	1978-08-14	1981-03-03	Steven Lehmbeck	Nebulizer attachment
US4198969A (en) *	1978-10-06	1980-04-22	Baxter Travenol Laboratories, Inc.	Suction-operated nebulizer
US4453542A (en) *	1980-12-08	1984-06-12	Vortran Corporation	Vortex-generating medical products
US4775622A (en) *	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US5218091A (en) *	1982-08-13	1993-06-08	Zymogenetics, Inc.	Glycolytic promoters for regulated protein expression: protease inhibitor
US4599311A (en) *	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
EP0162854A1 (en) *	1983-11-28	1985-12-04	Vortran Corporation	Gas-powered nebulizer
US4711848A (en)	1984-03-14	1987-12-08	Zymogenetics, Inc.	Site specific mutagenesis in alpha-1-antitrypsin
US4940661A (en) *	1984-05-17	1990-07-10	Genentech, Inc.	Metallothionein transcription control sequences and use thereof
US4931373A (en) *	1984-05-25	1990-06-05	Zymogenetics, Inc.	Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en)	1984-06-14	1988-03-22	Chiron Corporation	Active site modified protease α-1-antitrypsin inhibitors
US4752576A (en) *	1984-06-14	1988-06-21	Chiron Corporation	Expression of α-1 antitrypsin in yeast
US4837148A (en) *	1984-10-30	1989-06-06	Phillips Petroleum Company	Autonomous replication sequences for yeast strains of the genus pichia
US5013652A (en) *	1986-10-14	1991-05-07	Genex Corporation	Composite yeast vectors
US5166134A (en) *	1986-12-24	1992-11-24	John Lezdey	Treatment of allergic rhinitis
US5114917A (en) *	1986-12-24	1992-05-19	John Lezdey	Treatment of inflammation using alpha 1-antichymotrypsin
US4839283A (en) *	1986-12-30	1989-06-13	Zymogenetics, Inc.	Method of expressing alpha-1-antitrypsin in yeast
JP2656944B2 (ja) *	1987-04-30	1997-09-24	クーパーラボラトリーズ	タンパク質性治療剤のエアロゾール化
US4929555A (en) *	1987-10-19	1990-05-29	Phillips Petroleum Company	Pichia transformation
US6068994A (en) *	1989-08-07	2000-05-30	Chiron Corporation	Ubiquitin expression system
FR2660509B1 (fr) *	1990-03-29	1993-11-19	Alcatel Cit	Etage differentiel de sortie d'equipement electronique.
US5012652A (en) *	1990-09-21	1991-05-07	Carrier Corporation	Crankcase heater control for hermetic refrigerant compressors
US5134119A (en) *	1990-10-16	1992-07-28	Lezdey John	Treatment of inflammation using 358 substituted alpha-antitrypsin
US5114953A (en) *	1990-11-21	1992-05-19	University Of Florida	Treatment for tissue ulceration
US5268384A (en) *	1990-11-21	1993-12-07	Galardy Richard E	Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5892112A (en) *	1990-11-21	1999-04-06	Glycomed Incorporated	Process for preparing synthetic matrix metalloprotease inhibitors
US5256657A (en) *	1991-08-19	1993-10-26	Sterling Winthrop, Inc.	Succinamide derivative matrix-metalloprotease inhibitors
TW282490B (da) *	1992-12-15	1996-08-01	Ciba Geigy Ag
US5594106A (en) *	1993-08-23	1997-01-14	Immunex Corporation	Inhibitors of TNF-α secretion
WO1996004377A1 (en) *	1994-08-05	1996-02-15	Chiron Corporation	Production of tissue factor pathway inhibitor
US5780014A (en) *	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US5780440A (en) *	1996-06-17	1998-07-14	Protease Sciences Inc.	Treatment of pulmonary disease with protease inhibitors
US6610683B2 (en) *	1996-09-12	2003-08-26	Idun Pharmaceuticals, Inc.	Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
EP0852951A1 (de) *	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69834533T2 (de) *	1997-10-01	2006-10-12	Dsm Ip Assets B.V.	Verfahren zur Protein-Herstellung
US20010006939A1 (en) *	1997-10-03	2001-07-05	Ralph W. Niven	Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5972986A (en) *	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AU1905799A (en) *	1997-12-22	1999-07-12	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
KR20010033473A (ko) *	1997-12-23	2001-04-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	Ａｃｅ 저해제-ｍｍｐ 저해제의 병용 제제
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
AU3511500A (en) *	1999-03-05	2000-09-21	Trustees Of University Technology Corporation, The	Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
CZ20022413A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
US6991824B2 (en) *	2000-05-02	2006-01-31	Ventria Bioscience	Expression of human milk proteins in transgenic plants
US20020099013A1 (en) *	2000-11-14	2002-07-25	Thomas Piccariello	Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) *	2000-12-18	2007-07-24	Arriva Pharmaceuticals, Inc.	Multifunctional protease inhibitors and their use in treatment of disease
PA8539301A1 (es) *	2001-02-14	2002-09-30	Warner Lambert Co	Inhibidores de la metaloproteinasa de la matriz
US6544497B2 (en) *	2001-02-15	2003-04-08	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
JP2003024076A (ja) *	2001-07-12	2003-01-28	Kirin Brewery Co Ltd	Ｔｐｏ変異体タンパク質
FR2832569B1 (fr) *	2001-11-22	2007-04-27	Evolium Sas	Procede de transmission de communications dans un systeme de telecommunication de type cellulaire utilisant des bandes de frequences porteuses adjacentes
US20030211548A1 (en) *	2002-01-29	2003-11-13	Oncolmmunin, Inc.	Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
EP1685160A1 (en) *	2003-11-10	2006-08-02	Arriva-Prometic Inc.	Dry recombinant human alpha 1-antitrypsin formulation

2004
- 2004-11-11 DK DK04811377.3T patent/DK1684719T3/da active
- 2004-11-11 PT PT04811377T patent/PT1684719E/pt unknown
- 2004-11-11 EP EP04811377A patent/EP1684719B1/en not_active Expired - Lifetime
- 2004-11-11 SI SI200431814T patent/SI1684719T1/sl unknown
- 2004-11-11 ES ES04811377T patent/ES2375706T3/es not_active Expired - Lifetime
- 2004-11-11 WO PCT/US2004/038650 patent/WO2005048985A2/en active Application Filing
- 2004-11-11 JP JP2006540034A patent/JP2007511539A/ja active Pending
- 2004-11-11 PL PL04811377T patent/PL1684719T3/pl unknown
- 2004-11-11 AT AT04811377T patent/ATE530165T1/de active
- 2004-11-11 CA CA002545855A patent/CA2545855A1/en not_active Abandoned
- 2004-11-11 US US10/579,088 patent/US20080312136A1/en not_active Abandoned
- 2004-11-11 AU AU2004290587A patent/AU2004290587B2/en not_active Ceased
2010
- 2010-02-26 US US12/714,432 patent/US20100286066A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI1684719T1 (sl)	2012-07-31
CA2545855A1 (en)	2005-06-02
JP2007511539A (ja)	2007-05-10
US20100286066A1 (en)	2010-11-11
WO2005048985A3 (en)	2006-03-23
ATE530165T1 (de)	2011-11-15
PL1684719T3 (pl)	2012-11-30
PT1684719E (pt)	2012-02-03
EP1684719B1 (en)	2011-10-26
WO2005048985A2 (en)	2005-06-02
US20080312136A1 (en)	2008-12-18
AU2004290587B2 (en)	2010-08-12
AU2004290587A1 (en)	2005-06-02
EP1684719A2 (en)	2006-08-02
ES2375706T3 (es)	2012-03-05

Publication	Publication Date	Title
DK1684719T3 (da)	2012-01-30	Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
NO20042596L (no)	2004-06-21	Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
NO20064347L (no)	2006-09-26	Substituerte 1,2,3,4-tetrahydroisokinolinderivater
MY143795A (en)	2011-07-15	Tetrahydropyridoindole derivatives
MXPA04004842A (es)	2004-08-02	Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es)	2004-08-02	Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DE602005021770D1 (de)	2010-07-22	Indol-1-yl-essigsäurederivate
EP1562897A4 (en)	2007-06-27	PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
SG146648A1 (en)	2008-10-30	Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
DK1389137T3 (da)	2006-10-30	Sammensætninger til lungelægemiddellevering af protein
YU87202A (sh)	2006-05-25	Derivati arilmetilamina koji se koriste kao inhibitori triptaze
WO2006032115A3 (en)	2006-08-03	Composition against cardiovascular diseases
WO2003066597A3 (en)	2004-04-01	Guanidino compounds
RS44204A (en)	2007-06-04	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20073575L (no)	2007-09-13	Farmasoytiske sammensetninger for behandling av cellulitt
PA8525801A1 (es)	2002-08-29	Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
RS11104A (en)	2006-12-15	Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
RS44304A (en)	2007-06-04	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006136175A3 (en)	2007-09-20	Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor
WO2023069514A3 (en)	2023-06-01	Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
AU2002333536A1 (en)	2003-03-24	Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
DK0561882T3 (da)	1994-10-03	Hydroxamsyrederivater, som inhiberer lipoxygenase
MXPA04005033A (es)	2004-08-11	Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
BR0009778A (pt)	2002-01-02	Composições antifúngicas de pseudomicina e métodos para utilização das mesmas
ATE293983T1 (de)	2005-05-15	Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie